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direct consequence of their distinct structures, making the understanding of these structures and their biophysical interactions
fundamental to understanding prions and their related diseases. The insolubility and inherent disorder of prions have made their
structures difficult to study, particularly in the case of the infectious form of the mammalian prion protein PrP. Many investigators
have therefore preferred to work with peptide fragments of PrP, suggesting that these peptides might serve as structural and
functional models for biologically active prions. We have used x-ray fiber diffraction to compare a series of different-sized frag-
ments of PrP, to determine the structural commonalities among the fragments and the biologically active, self-propagating
prions. Although all of the peptides studied adopted amyloid conformations, only the larger fragments demonstrated a degree
of structural complexity approaching that of PrP. Even these larger fragments did not adopt the prion structure itself with detailed
fidelity, and in some cases their structures were radically different from that of pathogenic PrPSc.INTRODUCTIONPrion diseases are diseases caused by prions, proteins hav-
ing self-propagating aberrant folds. The key term is self-
propagating: the distinct prion structures themselves
catalyze the transition from the normal structure to the aber-
rant structure, and thus give rise to heritable characteristics
encoded in the protein structure. Prion diseases are thus dis-
orders of abnormal molecular structure and the anomalous
transitions between normal and aberrant molecular folds.
Self-propagation was originally recognized in prions
derived from the mammalian prion protein (PrP); the term
prion was coined to describe the PrP-derived, protein-only
infectious pathogen found in scrapie, a neurodegenerative
disease of sheep and goats (1). PrP prions have since been
implicated in related diseases in bovines, cervids, and hu-
mans; these diseases are sometimes called the transmissible
spongiform encephalopathies.
Amyloid diseases, which include all currently known
prion diseases, are diseases associated with abnormal de-
posits of misfolded proteins in the amyloid structural
form. This form, cross-b structure, is a simple motif thatSubmitted November 19, 2014, and accepted for publication January 13,
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0006-3495/15/03/1548/7 $2.00consists of b-strands extending roughly perpendicular to
the axes of long filaments (fibrils), forming sheets running
parallel to the fibril axis. It is now widely held (2–4) that
the aberrant protein folds found in many amyloid diseases
are self-propagating. Thus the structurally determined,
self-propagating properties of PrPSc (the infectious form
of PrP (5)) are common to the distinct aberrant folds of other
proteins, including the Alzheimer’s disease–associated pep-
tide Ab, the Parkinson’s disease–associated protein a-synu-
clein, and the microtubule-associated protein tau, which is
associated with a number of amyloid neurodegenerative dis-
eases including Alzheimer’s.
The self-propagating properties of prions are derived
from their structures and structural interactions. Structural
studies of PrPSc have been limited and extremely difficult,
owing to difficulties in purification and a high degree of
structural disorder. Limited proteolysis of PrPSc removes
~65 residues from the N-terminus to form PrP 27–30, which
retains prion infectivity (6), and useful information has been
obtained from x-ray fiber diffraction (7) and electron micro-
scopy (EM) (8–10) of this form. Many researchers, however,
have preferred to use much smaller peptides as structural
and functional models for biologically active PrPSc (11–
14). Over the past century, many structural studies of amy-
loids in general have been reported, dating back to the
pioneering work of Astbury (15). These have included
studies (12,16,17) by fiber diffraction, crystallography, and
EM, and more recently solid-state NMR (ssNMR). How-
ever, in most cases (a small number of ssNMR studies are
exceptions), either the data are poor and the models
extremely limited, or the amyloids studied were not shownhttp://dx.doi.org/10.1016/j.bpj.2015.01.008
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ties of biologically and pathologically important amyloids
are unique consequences of their molecular structures, so
studies of generic (but not self-propagating) amyloids tell
us little about the biological mechanisms of pathological
amyloids. This is not to say that work on simple amyloid
structures has not been valuable—it provided an essential
starting point. But it leaves many questions unanswered.
Most of the fiber diffraction studies and all of the crystal-
lographic studies of amyloids have targeted small amyloido-
genic fragments of biologically significant amyloids
(12,13,18–21). These fragments share a generic cross-b
architecture found in nonphysiological amyloids derived
from a number of complete proteins, but many of those pro-
teins (15) form amyloids only after exposure to nonphysio-
logical conditions such as high temperature or extreme pH,
making their formation and possibly their structures sub-
stantially different from spontaneously forming biological
amyloids. The generic architectures of these fragments
and nonphysiological amyloids do not have the level of
complexity found in biologically significant amyloids such
as the b-solenoids (7,9,22,23) of HET-s and PrPSc or the
U-shaped two-b-strand structures found in Ab (24,25).
More significantly, generic amyloid structures have not
been shown to share the self-propagating character of the
structurally more complex prions.
Because the distinctive biological activity of PrPSc is a
direct result of its structure, simpler model systems must
share the structural features of biological prions to be maxi-
mally useful. In this article, we use x-ray fiber diffraction to
characterize a series of different-sized fragments of PrP.
Using these structural characterizations, we have deter-
mined the structural commonalities among the fragments
and compared these structural features with those found in
biologically active, self-propagating PrP prions.MATERIALS AND METHODS
Peptide purification
Four peptide fragments of PrP, PrP21 (26), PrP55 (27), PrP89, and PrPSc106
(28) (Table 1), as well as a prion protein paralog similar to PrP55, Shadoo
(29,30) (Sho), were examined. The amino acid sequences of the fragments
corresponded to fragments of human (Hu), mouse (Mo), and bank vole
(BV) PrP.TABLE 1 Peptides used for fiber diffraction
Name
Size (amino
acids)
Corresponding
PrP residues Source Reference
PrP21 21 HuPrP(106–126) synthetic (26)
PrP55 55 MoPrP(89–143,
P101L)
synthetic (27)
PrP89 (MoPrP89,
BVPrP89)
89 MoPrP(89–177) recombinant
PrPSc106 106 BVPrP(90–178) mouse brain (28)
MoPrP(D23–88,
D141–176)HuPrP(106–126) (PrP21) was obtained from Bachem (Torrance, CA),
and fibrillized in 20 mM Tris-HCl pH 8.0, following the published protocol
(31) as closely as possible.
MoPrP(89–143,P101L) (PrP55), a generous gift from Dr. David Wem-
mer (University of California, Berkeley), was synthesized as described
(32). The lyophilized peptide was resuspended in 20 mM sodium acetate,
pH 5.0, 20% in acetonitrile, and 20 mM in sodium chloride. The solution
was allowed to fibrillize at room temperature for two to three weeks before
fibers were prepared.
Constructs encoding mouse Shadoo (Sho) (residues 25 to 122) or human
Sho (residues 25 to 126), both with an N-terminal His tag (MKHHHHHH),
were inserted into the pET-11a vector; recombinant Sho was expressed in
Rosetta2(DE3) Escherichia coli (EMD Millipore, Billerica, MA). Cells
were lysed using Lysonase (EMD Millipore, Billerica, MA) and recombi-
nant Sho was purified by immobilized metal affinity chromatography using
TALON resin (Clontech, Mountain View, CA). The N-terminal His tags
were not removed before fibril formation. Purified recombinant mouse
and human Sho were dialyzed against 20 mM sodium phosphate pH 7.4,
150 mM NaCl (PBS) and concentrated using an Amicon Ultra 3K MW cut-
off spin filter (EMD Millipore). Proteins were diluted to 1 mg/ml in PBS
and incubated at 37C with shaking for a period of 5 days. Fibrillization
was monitored using Thioflavin T fluorescence. Aliquots of the amyloid
preparations were snap-frozen in liquid nitrogen and stored at -80C.
MoPrP(89–177) (MoPrP89) and BVPrP(90–178) (BVPrP89) were ex-
pressed recombinantly. The BVPrP89 used for this study carried the I109
polymorphism. The sequences spanning residues 89–177 of murine PrP
and 90–178 of bank vole PrP were cloned into pET11a and expressed in
BL21 DE3 CodonPlus-RP (Stratagene). Purification was as described
(33), omitting the final oxidation step to form the disulfide bond in recPrP
constructs containing the C-terminal residues 178 to 230. MoPrP89 and
BVPrP89 lyophilisates were resuspended in 10 M urea at a concentration
of 10 mg/ml. For the induction of fibril formation, the recombinant peptides
were diluted to 1 mg/ml and adjusted to either 1 M urea (50 mM citrate
buffer, pH 3; 0.2 M NaCl) or 4 M urea (50 mM sodium acetate buffer
pH 5; 0.2 MNaCl). Samples were incubated for 48 h at 37C under constant
agitation at 900 rpm. After amyloid formation samples were spun down for
30 min at 100,000 g and resuspended in double-distilled water to remove
high concentrations of urea and salts.
PrPSc106 was purified from the brains of RML-infected Tg8872 mice ex-
pressing PrP(D23–88,D141–176) (34). The purification was based on the
specific precipitation of PrPSc106 by phosphotungstic acid (PTA) and
also included a limited digestion with proteinase K. PTA-precipitated
PrPSc106 was centrifuged through a sucrose cushion to remove extraneous
lipids, pelleted to remove the sucrose, and resuspended in concentrated
form in water (7).
The fibrillar structure of the aggregates was confirmed by EM.Fiber diffraction
Fibers were prepared (35) by suspending a 5 to 10 ml drop of fibril suspen-
sion between two glass rods, either tipped with beeswax or silanized and
sanded at the tips, ~1.5 mm apart. The fibers were allowed to dry for a
period of hours to days in a closed chamber under high humidity (98% in
vapor equilibrium with saturated potassium sulfate or nominal 100% in
equilibrium with water). Some fibers were allowed to dry at ~86% relative
humidity in equilibrium with saturated potassium chloride; the effect of this
lower humidity on the PrP55 fibers is discussed below.
Diffraction data were collected at beamline 4-2 at the Stanford Synchro-
tron Radiation Laboratory (Menlo Park, CA). Some preliminary data and
the data from the 98% humidity PrP55 fibers were collected at the BioCAT
beamline of the Advanced Photon Source synchrotron, Argonne National
Laboratory (Argonne, IL). Fibers were dusted with calcite and specimen-
to-detector distances were determined from the 012 calcite diffraction
ring at 3.8547 A˚ resolution and the 104 ring at 3.0355 A˚ (36); for brain-
derived samples, specimen-to-detector distances were taken from dustedBiophysical Journal 108(6) 1548–1554
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using the program WCEN (37) to determine experimental parameters and
positions of reflections.Electron microscopy
Samples at concentrations of ~1 mg/ml or less were applied to continuous
carbon film on 400 square mesh copper EM grids (Electron Microscopy
Sciences, Hatfield, PA, or Ted Pella, Redding, CA). The grids were stained
with a combination of 2% uranyl formate and 1% uranyl acetate (PrP21,
PrP55), or with 2% uranyl acetate, and micrographs were collected on an
FEI T-12 operating at 100 keV (PrP21) (FEI, Hillsboro, OR), a Philips
CM-12 operating at 80 keV (PrP55), or an FEI Tecnai F20 at 80 kV
(PrP89, PrPSc106, and Sho).RESULTS AND DISCUSSION
Electron micrographs (Fig. 1) showed that all of the samples
under study formed fibrils.
PrP consists of ~200 amino acids. A four-turn, left-
handed b-helix has been proposed (9) as a key element in
the structure of PrP 27–30; fiber diffraction data support
this model (7). X-ray fiber diffraction patterns from the
four peptide fragments of PrP are shown in Fig. 2 and are
compared in the following paragraphs with those obtained
from the ~140-amino-acid, brain-derived PrP 27–30 (7).FIGURE 1 Electron micrographs from amyloid fibrils show that all sam-
ples fibrillized. (A) PrP21. (B) PrP55. (C) MoPrP89, refolded in 1 M urea at
pH 3. (D) MoPrP89, refolded in 4 M urea at pH 5. (E) BVPrP89, refolded in
1M urea at pH 3. (F) PrPSc106. (G) Sho. Scale bar applies to all panels.
Appearances vary because of differences in staining, sources, and electron
microscopes, but all samples have clearly fibrillized.PrP21
Diffraction from PrP21 (Fig. 2 A) is dominated by a very
strong intensity on the meridian (the axis parallel to the fibril
axis) at 4.75 A˚. This intensity is characteristic of cross-b
structure and corresponds to the spacing between b-strands.
A weaker but clear meridional intensity at 9.5 A˚ shows that
the repeating unit contains not one, but two b-strands along
the fibril axis. A series of broad intensities on the equator
(the axis through the origin perpendicular to the meridian)
includes maxima at 8.5, 7.5, and 5.5 A˚. This pattern is
strongly indicative of a simple or generic amyloid structure
(7,17,23), with b-sheets stacked ~8 A˚ apart. The most likely
structure that would produce this pattern is that of an anti-
parallel b-sheet. A parallel sheet would have to include a
large meander between two extremely short strands, a
very implausible structure, or an equally implausible
arrangement in which the repeating unit was two out-of-reg-
ister parallel strands. Neither of these structures has ever
been observed, whereas for short peptides such as PrP21,
antiparallel arrangements are not at all uncommon (38).
Details notwithstanding, the structure is clearly a stacked
b-sheet with a two-strand repeat along the fibrillar axis,
and is very different from the solenoidal structure proposed
for PrP 27–30 (7).
The amyloid form of PrP21 has been shown to be toxic in
cell culture (26), but not self-propagating. Previously pub-
lished fiber diffraction patterns from PrP21 (13) did not
include a meridional 9.5 A˚ reflection, but fiber diffractionBiophysical Journal 108(6) 1548–1554was not a major part of that study, and the use of film for
recording diffraction, an in-house sealed tube x-ray gener-
ator, and poorly oriented fibers makes it unsurprising that
this feature was not seen.
Our data show that this fragment has a stacked-sheet
structure with a two-strand repeating unit, differing from
an ssNMR model (31) (a single-strand-repeat, parallel in-
register stacked sheet). Although we attempted to duplicate
the fibrillization conditions of the ssNMR study, it is
FIGURE 2 X-ray fiber diffraction patterns from
fibers of PrP fragments. (A) PrP21. (B) PrP55 at
~98% relative humidity. (C) PrP55 at ~86% rela-
tive humidity. (D) MoPrP89 refolded in 1 M urea
at pH 3. (E) MoPrP89 refolded in 4 M urea at
pH 5. (F) BVPrP89 refolded in 1 M urea at
pH 3. (G) PrPSc106. White arrowheads: meridional
cross-b diffraction at ~4.8 A˚ resolution. Black
arrowheads: meridional diffraction at ~9.6 A˚ in
(A), (B), (C), and (G), and also at ~6.4 A˚ in (G).
Arrows: equatorial diffraction at 8 to 10 A˚ in (A),
(C), and (D). The inset in (B), which includes the
black arrowhead, uses a more intense color table
to show the weak meridional intensity at 9.6 A˚
more clearly. Most panels include sharp crystalline
rings from calcite, used as a standard to determine
sample-to-detector distance. In (G), diffraction
from PrPSc106, the only brain-derived sample, in-
cludes many intensities attributed to lipids (7),
including an intense meridional intensity at ~4.2 A˚.
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solution conditions that different amyloid structures (paral-
lel and antiparallel) could form under very similar condi-
tions. However, in either case, the peptide clearly has a
stacked b-sheet structure, and not the structure of PrP
27–30 (7).FIGURE 3 X-ray fiber diffraction patterns from fibers of the nonprion
protein Shadoo (Sho), which is a paralog of PrP. (A) Mouse Sho. (B) Human
Sho. Meridional intensities at ~9.6 A˚ (insets, black arrowhead) show that
the repeating unit along the filament axis has the thickness of two b-strands.
The inserts, which include the black arrowheads, use a more intense color
table to show the weak meridional intensities at 9.6 A˚ more clearly.PrP55
Diffraction patterns from PrP55 vary in appearance, depend-
ing on the conditions of amyloid formation and fiber diffrac-
tion specimen preparation, with a particular sensitivity to
humidity (Fig. 2, B and C). In all cases, there is strong
cross-b meridional diffraction at 4.75 A˚, and a weaker
reflection at 9.5 A˚. The 9.5 A˚ reflection was seen more
clearly in patterns from low-humidity fibers, which is prob-
ably a consequence of low background scattering, character-
istic of low-humidity patterns. In high-humidity patterns
(Fig. 2 B), there are broad equatorial intensity maxima at
~20 A˚ and 10.3 A˚. In low-humidity patterns (Fig. 2 C),
the equator is dominated by a broad, strong maximum at
~8 A˚, with no other significant features. The low-humidity
equator is typical of a stacked-sheet amyloid, whereas the
high-humidity equator is much more consistent with diffrac-
tion from a roughly cylindrical structure such as a b-sole-
noid. The marked differences between diffraction patterns
to be expected from b-solenoidal and stacked-sheet struc-
tures have been discussed with calculated and experimental
examples elsewhere (7,23,39). The persistence of the merid-
ional 9.5 A˚ reflection suggests that the high-humidity struc-
ture has simply collapsed into a stacked-sheet structure,
supporting the hypothesis that the high-humidity structure
is indeed a solenoid. These patterns are strikingly analogous
to those seen in high and low humidity for the fungal prion
HET-s (39), where the solenoidal structure of the high-
humidity form has been independently determined by
ssNMR (22). The high-humidity patterns, supported bythe transition observed at lower humidity, strongly support
a two-rung solenoidal model for PrP55. The low-humidity
patterns also resemble the patterns obtained from the amy-
loid form (40) of the PrP paralog Sho (29,30) (Fig. 3), sug-
gesting the possibility that the Sho structure may also
include a collapsed two-rung solenoid.
PrP55 shares some of the biological properties of PrPSc,
being infectious in transgenic mice expressing PrP(P101L)
at a level similar to that of wild-type PrP (27,41). Our
PrP55 fiber diffraction data depend on humidity and are
similar to but distinctly different from previously published
patterns (19), showing that this peptide can be polymorphic.
The samples used in earlier work (19) were prepared in 50%
acetonitrile, with no humidity control, whereas our samples
were in 20% acetonitrile, and we found humidity to be a
critical determinant of the diffracting structure. Since the
equatorial diffraction from our high-humidity fibers sug-
gests that the structure may be b-solenoidal, PrP55 may
be a better model for PrPSc than PrP21, but it still lacks
key elements of the PrP 27–30 (and by implication, theBiophysical Journal 108(6) 1548–1554
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repeating unit is a two-rung structure rather than the four-
rung structure (7,9) proposed for PrP 27–30. PrP55 contains
barely enough peptide to make a complete two-rung struc-
ture, although a structure might be built using a total of
five b-strands instead of six, with highly efficient turns be-
tween the strands. Such a model structure would probably
not, however, reflect the PrPSc structure in detail; it is quite
likely that the infectivity of PrP55 comes from heteroge-
neous seeding (42–45), that is, seeding between distinct
amyloid architectures. PrP55 might be long enough to
contain a structured segment that can act as a seed, in
contrast to PrP21. Such a seed structure would contain ele-
ments of the PrPSc structure, and to that extent would be a
partial structural model, but it would still not contain all
of the important molecular interactions found in the true
structure.PrP89
MoPrP89 and BVPrP89 (Table 1) represent equivalent se-
quences of 89 residues from mouse and bank vole PrP
respectively. Bank vole PrP has been shown to adopt an in-
fectious conformation spontaneously when expressed in the
brains of transgenic mice (46). Refolded recombinant (rec)
MoPrP89 and BVPrP89 gave two distinct types of diffrac-
tion pattern, depending on the sequence and the conditions
of refolding. These two pattern types were strongly reminis-
cent of those obtained from recombinant and brain-derived
PrP (7), from HET-s depending on folding conditions
(23,44,45), and from PrP55 as described in the previous sec-
tion. The pattern from MoPrP89 refolded in 1 M urea at
pH 3 (Fig. 2 D) was very similar to that of recSHaPrP
(90–231) or recMoPrP (89–230) (7,47), with strong merid-
ional cross-b diffraction and an equator dominated by strong
intensities at 14 and 10 A˚, strongly indicating a generic
stacked-sheet structure. In contrast, patterns from both
MoPrP89 refolded in 4 M urea at pH 5 (Fig. 2 E) and
BVPrP89 refolded in 1 M urea at pH 3 (Fig. 2 F) include
a series of equatorial intensities progressively diminishing
as the distance from the origin increases, characteristic of
a cylindrical structure such as a b-solenoid (7,23). None
of the patterns included meridional diffraction other than
the cross-b diffraction at 4.8 A˚, but the meridional inten-
sities from the 19.2 A˚ four-b-strand repeat observed in pat-
terns from brain-derived PrP 27–30 (7) are weak, as would
be expected from a four-b-strand structure, and may well
have been reinforced by some sort of decoration of the
four-strand protein structure by the GPI anchor, brain lipids,
or other such molecules absent from the recombinant prep-
aration. The PrP 27–30 patterns (7) include a number of
strong intensities indicative of the presence of an ordered
lipid domain.
The patterns from MoPrP89 and BVPrP89 folded under
suitable conditions are thus consistent with the suggestionBiophysical Journal 108(6) 1548–1554that the refolded structure could be that of a multirung sole-
noid, such as the b-solenoidal structure proposed (7,9) for
PrP 27–30. Although this is of necessity a limited conclu-
sion, it is nevertheless an encouraging advance from struc-
tural studies (7) of recSHaPrP (90–231) and recMoPrP
(89–230); diffraction from those constructs indicated the
presence only of stacked-sheet structures, in contrast to
diffraction from brain-derived PrP 27–30. This fragment
may therefore have some value as a model for PrPSc.PrPSc106
Diffraction patterns from brain-derived PrPSc106 reflect a
considerable degree of disorder, and in some cases even
the cross-b reflection is difficult to discern, but in favorable
cases diffraction patterns bearing distinct similarities to
those of brain-derived PrP 27–30 (7) can be obtained
(Fig. 2 F). Like the PrP 27–30 patterns, they include
numerous intensities attributable to lipids or lipid-detergent
assemblies, but also meridional maxima at 9.6, 6.4, and
4.8 A˚, corresponding to the second, third, and fourth orders,
respectively, of a 19.2 A˚ repeat, the size of a four-stranded
b-sheet. The breadth and weakness of the 4.8 A˚ cross-b
reflection are strongly reminiscent of the corresponding
reflection in the PrP 27–30 patterns. Although the lipid
diffraction makes equatorial measurements impossible in
these patterns, the 19.2 A˚ repeat is an encouraging indica-
tion of structural similarities between PrPSc106 and PrP
27–30.
PrPSc106 has been shown to support prion propagation in
transgenic mice (34) and shares the 19.2 A˚ repeat of PrP 27–
30. To that extent, it may be the best peptide model for
PrPSc. Its most obvious limitations are that it exhibits disor-
der comparable with, and at times greater than that of
PrP 27–30, and is consequently difficult to obtain high-
quality diffraction data from. Nevertheless, comparisons
of PrPSc106, PrP 27–30, and PrPSc may provide useful
insights.CONCLUSIONS
Although all of the peptides studied adopted amyloid con-
formations, as do many other peptide fragments of PrP
(12,18–21), only the larger fragments have a degree of struc-
tural complexity approaching that of PrP 27–30. In partic-
ular, only the larger fragments appear to have any type of
b-solenoidal structure, and even PrP55 is too small to adopt
the four-rung PrP 27–30 structure. Fragments of increasing
length show increasing similarity to PrP 27–30 (and by
implication to PrPSc), but from the point of view of under-
standing structure none has a real advantage over purified
PrPSc or PrP 27–30. In particular, the shorter peptides
(PrP21 and by implication anything shorter, and perhaps
even peptides as large as PrP55), although useful in
providing insight into the generic stacked-sheet structure
Truncated Forms of the Prion Protein PrP 1553that underlies amyloid structure in general, tell us little or
nothing about the structural and functional basis of self-
propagation in prions.
Although we interpret the PrP 27–30 data in terms of a
solenoidal structure, our conclusions do not depend on the
accuracy of that interpretation. Regardless of the structural
details, there are clearly at least two quite different struc-
tures that can be adopted by these peptides. The shorter pep-
tides have never been seen to adopt structures similar to that
of PrP 27–30, the self-propagating prion structure. This is
most probably because the short lengths are not sufficient
for the formation of complex amyloid structures. Although
the longer fragments may adopt variations of the prion
structure (the two-turn solenoid, for example), they do not
adopt the prion structure itself with high fidelity, and often
do not adopt any structure close to it.
It appears that the definitive property of prions, self-prop-
agation, is inextricably tied to a requisite level of structural
complexity. We have shown that this structural complexity
is not found in overly simple model systems. Longer models
that recapitulate the structural features found in prions tend
to have similar levels of structural disorder, indicating that
simple solutions for understanding the biophysical proper-
ties of prions remain elusive.AUTHOR CONTRIBUTIONS
W.W., H.W., S.B.P, and G.S. designed the research; W.W., H.W., J.S., A.K.,
W.B., M.M., J.C.W., and G.S. performed research and analysis; W.B. and
S.T. contributed research methods; W.W., H.W., J.S., A.K., J.C.W.,
S.B.P., and G.S. wrote the article; all authors contributed to the final article.ACKNOWLEDGMENTS
We thank the staff of beamline 4-2 at the Stanford Synchrotron Radiation
Lightsource (SSRL) and BioCAT at the Advanced Photon Source (APS).
We also thank Lillian Bloch and Aleksandra Kijac for assistance preparing
diffraction samples.
This work was supported by U.S. National Institutes of Health (NIH) grants
AG002132, AG021601, AG010770, and F31-AG040947. The SSRL is a
national user facility operated by Stanford University on behalf of the
U.S. Department of Energy (DOE), Office of Basic Energy Sciences. The
SSRL Structural Molecular Biology Program is supported by the DOE
and NIH. The APS is supported by the DOE. BioCAT is supported by
NIH grant 9 P41 GM103622. Some negative stain electron micrographs
were collected in the VUMC Cell Imaging Shared Resource, supported
by NIH grants.REFERENCES
1. Prusiner, S. B. 1982. Novel proteinaceous infectious particles cause
scrapie. Science. 216:136–144.
2. Holmes, B. B., and M. I. Diamond. 2012. Cellular mechanisms of pro-
tein aggregate propagation. Curr. Opin. Neurol. 25:721–726.
3. Prusiner, S. B. 2012. Cell biology. A unifying role for prions in neuro-
degenerative diseases. Science. 336:1511–1513.
4. Jucker, M., and L. C. Walker. 2013. Self-propagation of pathogenic
protein aggregates in neurodegenerative diseases. Nature. 501:45–51.5. Prusiner, S. B. 2007. Prions. In Fields Virology. D. M. Knipe, P. M.
Howley,., S. E. Straus, editors. Lippincott Williams &Wilkins, Phil-
adelphia, pp. 3059–3092.
6. McKinley, M. P., R. K. Meyer,., S. B. Prusiner. 1991. Scrapie prion
rod formation in vitro requires both detergent extraction and limited
proteolysis. J. Virol. 65:1340–1351.
7. Wille, H., W. Bian, ., G. Stubbs. 2009. Natural and synthetic prion
structure from X-ray fiber diffraction. Proc. Natl. Acad. Sci. USA.
106:16990–16995.
8. Wille, H., M. D. Michelitsch, ., S. B. Prusiner. 2002. Structural
studies of the scrapie prion protein by electron crystallography. Proc.
Natl. Acad. Sci. USA. 99:3563–3568.
9. Govaerts, C., H. Wille,., F. E. Cohen. 2004. Evidence for assembly of
prions with left-handed b-helices into trimers. Proc. Natl. Acad. Sci.
USA. 101:8342–8347.
10. Wille, H., C. Govaerts, ., S. B. Prusiner. 2007. Electron crystallog-
raphy of the scrapie prion protein complexed with heavy metals.
Arch. Biochem. Biophys. 467:239–248.
11. Inouye, H., and D. A. Kirschner. 2006. X-ray fiber and powder diffrac-
tion of PrP prion peptides. Adv. Protein Chem. 73:181–215.
12. Sawaya, M. R., S. Sambashivan,., D. Eisenberg. 2007. Atomic struc-
tures of amyloid cross-beta spines reveal varied steric zippers. Nature.
447:453–457.
13. Tagliavini, F., F. Prelli,., G. Forloni. 1993. Synthetic peptides homol-
ogous to prion protein residues 106-147 form amyloid-like fibrils
in vitro. Proc. Natl. Acad. Sci. USA. 90:9678–9682.
14. Helmus, J. J., K. Surewicz, ., C. P. Jaroniec. 2010. Conformational
flexibility of Y145Stop human prion protein amyloid fibrils probed
by solid-state nuclear magnetic resonance spectroscopy. J. Am.
Chem. Soc. 132:2393–2403.
15. Astbury, W. T., S. Dickinson, and K. Bailey. 1935. The x-ray interpre-
tation of denaturation and the structure of the seed globulins.
Biochem. J. 29:2351–2360.1.
16. Wasmer, C., A. Lange, ., B. H. Meier. 2008. Amyloid fibrils of the
HET-s(218-289) prion form a beta solenoid with a triangular hydropho-
bic core. Science. 319:1523–1526.
17. Jahn, T. R., O. S. Makin,., L. C. Serpell. 2010. The common archi-
tecture of cross-beta amyloid. J. Mol. Biol. 395:717–727.
18. Nguyen, J. T., H. Inouye,., D. A. Kirschner. 1995. X-ray diffraction
of scrapie prion rods and PrP peptides. J. Mol. Biol. 252:412–422.
19. Inouye, H., J. Bond,., D. A. Kirschner. 2000. Structural changes in a
hydrophobic domain of the prion protein induced by hydration and by
Ala—>Val and Pro—>Leu substitutions. J. Mol. Biol. 300:1283–
1296.
20. Salmona, M., M. Morbin,., F. Tagliavini. 2003. Structural properties
of Gerstmann-Straussler-Scheinker disease amyloid protein. J. Biol.
Chem. 278:48146–48153.
21. Apostol, M. I., J. J. Wiltzius,., D. Eisenberg. 2011. Atomic structures
suggest determinants of transmission barriers in mammalian prion dis-
ease. Biochemistry. 50:2456–2463.
22. Van Melckebeke, H., C. Wasmer,., B. H. Meier. 2010. Atomic-reso-
lution three-dimensional structure of HET-s(218-289) amyloid fibrils
by solid-state NMR spectroscopy. J. Am. Chem. Soc. 132:13765–
13775.
23. Wan, W., H. Wille, ., G. Stubbs. 2012. Degradation of fungal prion
HET-s(218-289) induces formation of a generic amyloid fold.
Biophys. J. 102:2339–2344.
24. McDonald, M., H. Box, ., G. Stubbs. 2012. Fiber diffraction data
indicate a hollow core for the Alzheimer’s ab 3-fold symmetric fibril.
J. Mol. Biol. 423:454–461.
25. Lu, J. X., W. Qiang,., R. Tycko. 2013. Molecular structure of b-am-
yloid fibrils in Alzheimer’s disease brain tissue. Cell. 154:1257–1268.
26. Forloni, G., N. Angeretti, ., F. Tagliavini. 1993. Neurotoxicity of a
prion protein fragment. Nature. 362:543–546.Biophysical Journal 108(6) 1548–1554
1554 Wan et al.27. Kaneko, K., H. L. Ball,., F. E. Cohen. 2000. A synthetic peptide ini-
tiates Gerstmann-Stra¨ussler-Scheinker (GSS) disease in transgenic
mice. J. Mol. Biol. 295:997–1007.
28. Muramoto, T., M. Scott,., S. B. Prusiner. 1996. Recombinant scrapie-
like prion protein of 106 amino acids is soluble. Proc. Natl. Acad. Sci.
USA. 93:15457–15462.
29. Premzl, M., L. Sangiorgio,., J. E. Gready. 2003. Shadoo, a new pro-
tein highly conserved from fish to mammals and with similarity to
prion protein. Gene. 314:89–102.
30. Watts, J. C., B. Drisaldi,., D. Westaway. 2007. The CNS glycoprotein
Shadoo has PrP(C)-like protective properties and displays reduced
levels in prion infections. EMBO J. 26:4038–4050.
31. Walsh, P., K. Simonetti, and S. Sharpe. 2009. Core structure of amyloid
fibrils formed by residues 106-126 of the human prion protein. Struc-
ture. 17:417–426.
32. Lim, K. H., T. N. Nguyen,., D. E. Wemmer. 2006. Solid-state NMR
structural studies of the fibril form of a mutant mouse prion peptide
PrP89-143(P101L). Solid State Nucl. Magn. Reson. 29:183–190.
33. Mehlhorn, I., D. Groth,., S. B. Prusiner. 1996. High-level expression
and characterization of a purified 142-residue polypeptide of the prion
protein. Biochemistry. 35:5528–5537.
34. Supattapone, S., P. Bosque, ., M. Scott. 1999. Prion protein of 106
residues creates an artificial transmission barrier for prion replication
in transgenic mice. Cell. 96:869–878.
35. McDonald, M., A. Kendall, ., G. Stubbs. 2008. Enclosed chambers
for humidity control and sample containment in fiber diffraction.
J. Appl. Cryst. 41:206–209.
36. Effenberger, H. K., K. Mereiter, and J. Zemann. 1981. Crystal structure
refinements of magnesite, calcite, rhodochrosite, siderite, smithonite,
and dolomite, with discussion of some aspects of the stereochemistry
of calcite type carbonates. Z. Kristallogr. 156:233–243.Biophysical Journal 108(6) 1548–155437. Bian, W., H. Wang,., G. Stubbs. 2006. WCEN: a computer program
for initial processing of fiber diffraction patterns. J. Appl. Cryst.
39:752–756.
38. Serpell, L. C., C. C. F. Blake, and P. E. Fraser. 2000. Molecular struc-
ture of a fibrillar Alzheimer’s A b fragment. Biochemistry. 39:13269–
13275.
39. Wan, W., and G. Stubbs. 2014. Fiber diffraction of the prion-forming
domain HET-s(218-289) shows dehydration-induced deformation of
a complex amyloid structure. Biochemistry. 53:2366–2370.
40. Daude, N., V. Ng,., D. Westaway. 2010. Wild-type Shadoo proteins
convert to amyloid-like forms under native conditions. J. Neurochem.
113:92–104.
41. Tremblay, P., H. L. Ball,., J. G. Safar. 2004. Mutant PrPSc conformers
induced by a synthetic peptide and several prion strains. J. Virol.
78:2088–2099.
42. Makarava, N., G. G. Kovacs, ., I. V. Baskakov. 2011. Genesis of
mammalian prions: from non-infectious amyloid fibrils to a transmis-
sible prion disease. PLoS Pathog. 7:e1002419.
43. Makarava, N., G. G. Kovacs,., I. V. Baskakov. 2012. A new mecha-
nism for transmissible prion diseases. J. Neurosci. 32:7345–7355.
44. Wan, W., W. Bian, ., G. Stubbs. 2013. Heterogeneous seeding of a
prion structure by a generic amyloid form of the fungal prion-forming
domain HET-s(218-289). J. Biol. Chem. 288:29604–29612.
45. Wan, W., and G. Stubbs. 2014. Heterogeneous seeding of HET-s(218-
289) and the mutability of prion structures. Prion. 8:1–5.
46. Watts, J. C., K. Giles,., S. B. Prusiner. 2012. Spontaneous generation
of rapidly transmissible prions in transgenic mice expressing wild-type
bank vole prion protein. Proc. Natl. Acad. Sci. USA. 109:3498–3503.
47. Legname, G., I. V. Baskakov, ., S. B. Prusiner. 2004. Synthetic
mammalian prions. Science. 305:673–676.
